Workflow
interference
icon
Search documents
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
Globenewswire· 2025-04-23 13:20
Core Insights - Silexion Therapeutics has announced a strategic collaboration with Catalent to advance its RNA interference (RNAi) cancer therapies, specifically targeting KRAS-driven cancers [1][4] - The collaboration will focus on the formulation development and clinical manufacturing of Silexion's siRNA candidate, SIL204, at Catalent's facility in Limoges, France [2][4] - Silexion aims to initiate human clinical trials for SIL204 in the first half of 2026, following promising preclinical results [4][5] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNAi therapies for solid tumors driven by KRAS mutations, which are prevalent in various cancers [6] - The company's first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer [6] - SIL204 is designed to target a broader range of KRAS mutations and has demonstrated significant efficacy in preclinical studies [3][6] Collaboration Details - Catalent will optimize both systemic and intratumoral delivery formulations of SIL204, supporting Silexion's dual-route development strategy [2][4] - The collaboration leverages Catalent's expertise in complex formulation development to enhance SIL204's stability, bioavailability, and delivery precision [4] - Silexion plans to conduct additional toxicology and pharmacodynamic studies throughout 2025, with regulatory submissions anticipated in late 2025 and early 2026 [5]
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Globenewswire· 2025-03-21 12:30
Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the PresentationGrand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies fo ...
数千万元!穹顶医疗完成A轮融资
思宇MedTech· 2025-02-24 04:28
合作伙伴征集:2025全球手术机器人大会 报名:首届全球眼科大会 | 展位有限 报名:首届全球心血管大会 | 奖项评选 报名:首届全球骨科大会 | 奖项评选 近日,专注于无创深脑神经调控技术的 西安穹顶医疗科技有限公司 成功完成 数千万元 A轮融资 。本轮融 资由 华方资本 与 讯飞创投 共同领投, 合盈资本 跟投, 行远致同 担任独家财务顾问。 资金将用于加速时间干涉技术(Temporal Interference,TI)在脑科学领域的探索,推动多场景产品方案 的临床注册、产品获证及商业化落地。 # 公司介绍 穹顶医疗成立于2019年11月,总部位于西安。公司专注于无创深脑神经调控技术的研发与应用,是该领域 的创新引领者。穹顶医疗深耕无创神经调控领域近10年,已掌握并实现人体TI无创深脑精准神经调控。公 司拥有60余项发明专利和实用新型专利,产品线涵盖科研与临床应用。 产 品与技术介绍 穹顶医疗的核心技术为时间干涉技术(TI),该技术通过高频电流在脑深部形成低频电场"包络",实现无 创、深脑、高精度、多靶点的神经调控。公司的第六代产品TIs EMO-1000/TIs CAP具备高精度刺激控制 功能,可输出不 ...